Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Chief Financial Officer | July 26, 2017 | July 28, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date July 26, 2017 · Filed July 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2017-07-26 transaction · row 1
1 source rowRow 1 · 2017-07-26 · Exercise / conversion · Acquired 4,000 · Balance 50,000 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2018-08-14 | Direct | 0 |
Reported balance
After 2017-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-26 · Exercise / conversion · Disposed 4,000 · Balance 0 F1: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2017 Filed Jul 28, 2017 20:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-17-046598 · doc4.xml · derivative · entry 2 Schoell Josef · CIK 0001597186 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 20:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 4,000 | $2.25 | $9,000.00 |
DisclosureSEC source: 0001209191-17-046598 · doc4.xml · nonDerivative · entry 1 Schoell Josef · CIK 0001597186 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:21 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001209191-17-019915 · doc4.xml · derivative · entry 1 Schoell Josef · CIK 0001597186 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.